Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase

Patent metadata

Field	Value
Publication number	US-2016263203-A1
Application number	US-201514984959-A
Country	US
Kind code	A1
Filing date	Dec 30, 2015
Priority date	Apr 18, 1997
Publication date	Sep 15, 2016
Grant date	—

Abstract

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

First claim

1 . An isolated polypeptide comprising 10 or more consecutive amino acids of SEQ. ID NO:2, which can elicit an adaptive immune response against human telomerase reverse transcriptase (hTRT; SEQ. ID NO:2).

2 . The isolated polypeptide of claim 1 , comprising 20 or more consecutive amino acids of SEQ. ID NO:2.

3 . The isolated polypeptide of claim 1 , comprising 50 or more consecutive amino acids of SEQ. ID NO:2.

4 . The isolated polypeptide of claim 1 , comprising 100 or more consecutive amino acids of SEQ. ID NO:2.

5 . The polypeptide of claim 1 , containing an amino acid sequence selected from SEQ. ID NO: 112, SEQ. ID NO: 113, SEQ. ID NO: 114, SEQ. ID NO:115, SEQ. ID NO: 116, and SEQ. ID NO: 117.

6 . The polypeptide of claim 1 , which is at least 98% identical to full-length hTRT (SEQ. ID NO:2).

7 . The polypeptide of claim 6 , which does not retain the telomerase catalytic activity of native human telomerase reverse transcriptase.

8 . A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

9 . An immunogenic composition that elicits an adaptive immune response against hTRT (SEQ. ID NO:2), comprising a peptide and an adjuvant, wherein the peptide comprises 10 or more consecutive amino acids of SEQ. ID NO:2.

10 . The composition of claim 9 , comprising 50 or more consecutive amino acids of SEQ. ID NO:2.

11 . The composition of claim 9 , wherein the adjuvant is selected from Freund's adjuvant, a mineral gel, aluminum hydroxide, lysolecithin, pluronic polyol, a polyanlon, a peptide, an oil emulsion, keyhole limpet hemocyanin (KLH), dinitrophenol (DNP), Bacillus Calmette-Guerin, and Corynebacterium parvum.

12 . A method for eliciting an immune response to telomerase reverse transcriptase protein in a subject, comprising administering to the subject the composition of claim 9 .

13 . The method of claim 12 , further comprising assessing whether a telomerase-specific immune response is elicited as a result of the administration.

14 . (canceled)

15 . (canceled)

16 . A chimeric molecule comprising a polypeptide that consists of 10 or more consecutive amino acids of SEQ. ID NO:2, and a second amino acid sequence, wherein the polypeptide fused to the second amino acid sequence forms a chimeric molecule that elicits an adaptive immune response.

17 . The chimeric protein of claim 16 , wherein the second protein is keyhole limpet hemocyanin.

18 . An immunogenic composition comprising the chimeric protein of claim 16 , and an adjuvant.

19 . (canceled)

20 . An immunogenic composition comprising the chimeric protein of claim 18 , and an adjuvant.

Assignees

• Geron Corp
• Univ Colorado Regents

Inventors

• Cech Thomas R
• Lingner Joachim
• Nakamura Toru M
• Chapman Karen B
• Morin Gregg B
• Harley Calvin B
• Andrews William H

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12Q1/6895

  for plants, fungi or algae · CPC title

• C12N2310/15

  Nucleic acids forming more than 2 strands, e.g. TFOs · CPC title

• C12N15/1137

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title